These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

COVID-19 vaccines work—but immunocompromised individuals may not produce as strong an immune response. Evusheld became the first treatment to protect this group before exposure to the virus when it received emergency authorization from the FDA in December 2021. The antibody therapy—made by AstraZeneca and given by injection to people at high risk of developing serious disease if they get COVID-19—is a combination of two monoclonal antibodies that soak up virus proteins to prevent them from infecting healthy cells. There is a downside of antibody-based treatments like Evusheld, however: viruses can mutate to become resistant to them. The FDA has warned that the therapy might not be as effective with newer Omicron variants compared to previous strains of SARS-CoV-2.

More Must-Reads from TIME

Contact us at

Augmented Job Training
Next-Level EV
Flash-Frozen Coffee to Go
Athletic Apparel for the Smartwatch Era
Meditate in the Metaverse